| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
Division of Endocrinology and Metabolism, Otaru City General Hospital, Otaru 047-8550, Japan. miyamatsuba@proof.ocn.ne.jp
OBJECTIVE: Inflammation has been suggested as a risk factor for the development of atherosclerosis, while some components of metabolic syndrome X have been related to inflammatory markers. We hypothesized that adipocyte secreting protein, adiponectin and leptin, for which have been demonstrated an association with metabolic syndrome X and coronary artery disease, may be associated with inflammatory markers in nondiabetic humans. DESIGN AND METHODS: We measured high-sensitivity C-reactive protein (hs-CRP), as an inflammatory marker, and adiponectin and leptin concentrations in 384 nondiabetic Japanese women (mean+/-s.e.m. age 53.6+/-0.8 Years, body mass index (BMI) 23.0+/-0.2 kg/m(2)) undergoing measurement of markers of metabolic syndrome X. RESULTS: The women who had a low-grade hs-CRP elevation (>2.0 mg/l) were significantly older and had higher BMI, body fat mass (BFM), total cholesterol (TC), triglyceride (TG), atherogenic index (AI=(TC-HDLC)/HDLC), where HDLC is high-density lipoproten-cholesterol), fasting blood glucose and leptin concentrations before and after adjustment for BMI or BFM, while lower HDLC and adiponectin concentrations before and after adjustment compared with women with normal CRP levels (<0.5 mg/l). BMI, BFM, TG, AI and leptin before and after adjustment were found to be correlated with hs-CRP levels, while HDLC and adiponectin before and after adjustment were inversely correlated (all P<0.0001). hs-CRP was independently associated with white blood cell count, blood urea nitrogen and AI and inversely with adiponectin/BFM in the stepwise regression analysis model. CONCLUSIONS: These data demonstrate a significant decrease in plasma adiponectin in low-grade chronic inflammation, and suggest that there is an important linkage between inflammation/adipose tIssue/atherosclerosis.
This article has been cited by other articles:
|
|
 |
|
  M. Broch, M. T. Auguet, R. Ramirez, M. Olona, C. Aguilar, A. Megia, M. J. Alcaide, R. Pastor, S. Martinez, E. Caubet, et al. Parallel downregulation of retinol-binding protein-4 and adiponectin expression in subcutaneous adipose tissue of non-morbidly obese subjects Eur. J. Endocrinol., July 1, 2009; 161(1): 87 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Aprahamian, R. G. Bonegio, C. Richez, K. Yasuda, L.-K. Chiang, K. Sato, K. Walsh, and I. R. Rifkin The Peroxisome Proliferator-Activated Receptor {gamma} Agonist Rosiglitazone Ameliorates Murine Lupus by Induction of Adiponectin J. Immunol., January 1, 2009; 182(1): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Teoh, A. Quan, K. W. A. Bang, G. Wang, F. Lovren, V. Vu, J. J. Haitsma, P. E. Szmitko, M. Al-Omran, C.-H. Wang, et al. Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E658 - E664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Saltevo, M. Vanhala, H. Kautiainen, and M. Laakso Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 328 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Peterlin, M. Bigal, S. Tepper, M Urakaze, F. Sheftell, and A. Rapoport Migraine and Adiponectin: Is There a Connection? Cephalalgia, May 1, 2007; 27(5): 435 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, H. Teoh, D. J. Stewart, and S. Verma Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1655 - H1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J George, S Patal, D Wexler, Y Sharabi, E Peleg, Y Kamari, E Grossman, D Sheps, G Keren, and A Roth Circulating adiponectin concentrations in patients with congestive heart failure Heart, October 1, 2006; 92(10): 1420 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kantartzis, K. Rittig, B. Balletshofer, J. Machann, F. Schick, K. Porubska, A. Fritsche, H.-U. Haring, and N. Stefan The Relationships of Plasma Adiponectin with a Favorable Lipid Profile, Decreased Inflammation, and Less Ectopic Fat Accumulation Depend on Adiposity Clin. Chem., October 1, 2006; 52(10): 1934 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Schulze, I. Shai, E. B. Rimm, T. Li, N. Rifai, and F. B. Hu Adiponectin and Future Coronary Heart Disease Events Among Men With Type 2 Diabetes Diabetes, February 1, 2005; 54(2): 534 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Schulze, E. B. Rimm, I. Shai, N. Rifai, and F. B. Hu Relationship Between Adiponectin and Glycemic Control, Blood Lipids, and Inflammatory Markers in Men With Type 2 Diabetes Diabetes Care, July 1, 2004; 27(7): 1680 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pischon, C. J. Girman, G. S. Hotamisligil, N. Rifai, F. B. Hu, and E. B. Rimm Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men JAMA, April 14, 2004; 291(14): 1730 - 1737. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
